Influence of multimorbidity on the risk of events in men with chronic coronary artery disease after myocardial infarction and percutaneous coronary intervention

Aim. To study the effect of multimorbidity on the risk of cardiovascular events (CVEs) in men with chronic coronary artery disease (CAD) after myocardial infarction (MI) and percutaneous coronary intervention (PCI).

Material and methods. A total of 101 men with chronic CAD after MI and PCI were included in the study (mean age 60,5±6,1 years). Of these, taking into account the non-inclusion criteria and consent to examination, 2 following groups were formed: first (n=39) — men without CVEs; 2^nd (n=39) — men with CVEs. In both groups, we studied the detection rate of grade I hypertension (HTN), class I obesity, hypercholesterolemia (HCE), and type 2 diabetes (T2D). The influence of HTN, obesity, HCE, and T2D on the risk of cardiovascular events was analyzed based on the calculation of contingency tables and Pearson's χ², as well as odds ratios (OR) with 95,0% confidence intervals (CI). The follow-up period for patients averaged 3,6±0,5 years.

Results. In men of group 2, compared with group 1 patients, grade I HTN, class I obesity, HCE were diagnosed more often in 1,3 (p=0,044), 1,4 (p=0,047), 1,2 (p=0,059) times, respectively. An increase in the risk of CVEs in men with chronic CAD, who underwent MI and PCI was associated with the detection of grade I HTN, class I obesity, HCE — OR 2,44 (CI: 1,88-6,75), OR 1,78 (CI: 1,56-4,62), OR 1,37 (CI: 1,11-4,17), respectively.

Conclusion. Thus, the detection rate of grade I HTN, class I obesity and HCE in men with chronic CAD and CVEs at long-term follow-up after MI and PCI was significantly higher compared to patients with chronic CAD without CVEs after PCI. At the same time, the detection of grade I HTN, class I obesity and HCE were associated with an increased risk of cardiovascular events.

1. Stable ischemic heart disease. Clinical Guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/1560-4071-2020-4076.

2. Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prophylaxis 2022. Russian National Recommendations. Russian Journal of Cardiology. 2023;28(5):5452. (In Russ.) doi:10.15829/1560-4071-2023-5452.

3. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Prevention of chronic non-infectious diseases in the Russian Federation. National Guidelines 2022. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) doi:10.15829/1728-8800-2022-3235.

4. Drapkina OM, Samorodskaya IV. Dynamics of regional indicators of mortality from cardiological causes in Russia in 2019-2020. Kardiologiia. 2022;62(10):16-25. (In Russ.) doi:10.18087/cardio.2022.10. n1926.

5. ESC/EACTS Recommendations for Myocardial Revascularization 2018. Russian Journal of Cardiology. 2019;(8):151-226. (In Russ.) doi:10.15829/1560-4071-2019-8-151-226.

6. Oganov RG, Denisov IN, Simanenkov VI, et al. Comorbid pathology in clinical practice. clinical recommendations. Cardiovascular Therapy and Prevention. 2017;16(6):5-56. (In Russ.) doi:10.15829/1728-8800-2017-6-5-56.

7. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.

8. Kobalava JD, Conradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.

9. Timofeev YS, Dzhioeva ON, Drapkina OM. Circulating biological markers of obesity: on the way to a systemic approach. Cardiovascular Therapy and Prevention. 2023;22(4):85-93. (In Russ.) doi:10.15829/1728-8800-2023-3551.

10. Kokozheva MA, Kutsenko VA, Mardanov BU, et al. Complex analysis of clinical and instrumental parameters of coronary blood flow in patients with acute forms of coronary heart disease on the background of type 2 diabetes mellitus. Cardiovascular Therapy and Prevention. 2023;22(5):3338. (In Russ.) doi:10.15829/1728-8800-2023-3338.

11. Tolpygina SN, Martsevich SY, Deev AD. Extended clinical and instrumental risk prediction scale for death and nonfatal cardiovascular complications in patients on the IBS PROGNOSIS register. Cardiovascular Therapy and Prevention. 2021;20(7):3060. (In Russ.) doi:10.15829/1728-8800-2021-3060.

12. Orlov VN. Manual of electrocardiography. M.: LLC "Medical Information Agency", 1999. p. 528. (In Russ.) ISBN: 5-89481-041-8.

13. Drapkina OM, Dzhioeva ON. Modern echocardiographic criteria for heart failure with preserved ejection fraction: not only diastolic dysfunction. Cardiovascular Therapy and Prevention. 2020;19(2):2454. (In Russ.) doi:10.15829/1728-88002020-2454.

14. Fletcher R, Fletcher S, Vagner E. Clinical epidemiology. Fundamentals of evidence-based medicine. Translated from English. M.: Media-Sfera, 1998. p. 352 (In Russ.) ISBN: 5-89084-011-8.

15. Boytsov SA, Shakhnovich RM, Tereshchenko SN, et al. Features of parenteral anticoagulant therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction — REGION-IM. Кardiologiia. 2022;62(10):3-15. (In Russ.) doi:10.18087/cardio.2022.10.n2238.

16. Boytsov SA, Drapkina OM, Shlyakhto EV, et al. ESSE-RF study (Epidemiology of cardiovascular diseases and their risk factors in the regions of the Russian Federation). Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007. (In Russ.) doi:10.15829/1728-8800-2021-3007.

17. Pereverzeva KG, Lukyanov MM, Andreenko EYu, et al. Outpatient registry of patients with myocardial infarction (REGATA): prospective follow-up data and outcomes. Кardiologiia. 2022;62(2):12-9. (In Russ.) doi:10.18087/cardio.2022.2.n1712.

18. Lukyanov MM, Andreenko EY, Smirnov AA, et al. Outpatient and polyclinic register of a multidisciplinary medical center (TERRA): general characteristics and first results. Cardiovascular Therapy and Prevention. 2023;22(6):3598. (In Russ.) doi:10.15829/1728-8800-2023-3598.